

Joseph A O'donoghue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3717576/publications.pdf>

Version: 2024-02-01

66
papers

3,528
citations

109264

35
h-index

138417

58
g-index

67
all docs

67
docs citations

67
times ranked

4221
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of regional tumor hypoxia using ¹⁸ F-fluoromisonidazole and ⁶⁴ Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po ₂ probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1493-1502.	0.4	183
2	First-in-Humans Imaging with ⁸⁹ Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	2.8	170
3	A Phase I/II Study for Analytic Validation of ⁸⁹ Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	3.2	163
4	Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³ Ra-dichloride in men with castration-resistant metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1384-1393.	3.3	160
5	⁸⁹ Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	3.3	130
6	First-in-Human Human Epidermal Growth Factor Receptor 2 Targeted Imaging Using ⁸⁹ Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 900-906.	2.8	126
7	Pilot Trial of Unlabeled and Indium-111 Labeled Anti Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7454-7461.	3.2	120
8	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	2.8	116
9	Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy. <i>Cancer Research</i> , 2007, 67, 7646-7653.	0.4	111
10	Noninvasive Multimodality Imaging of the Tumor Microenvironment: Registered Dynamic Magnetic Resonance Imaging and Positron Emission Tomography Studies of a Preclinical Tumor Model of Tumor Hypoxia. <i>Neoplasia</i> , 2009, 11, 247-IN3.	2.3	107
11	Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. <i>Nuclear Medicine and Biology</i> , 2005, 32, 623-630.	0.3	98
12	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	2.8	96
13	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-2442.	0.8	92
14	¹²⁴ I-huA33 Antibody PET of Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1173-1180.	2.8	85
15	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹ In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰ Y Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1066-1074.	2.8	76
16	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2707-2713.	3.2	73
17	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. <i>Radiology</i> , 2020, 295, 606-615.	3.6	73
18	Phase I clinical trial with fractionated radioimmunotherapy using ¹³¹ I-labeled chimeric G250 in metastatic renal cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1412-21.	2.8	72

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ¹⁷⁷ Lu-Satoreotide Tetraxetan. <i>Clinical Cancer Research</i> , 2019, 25, 6939-6947.	3.2	69
20	Pilot study of ⁶⁸ Ga-DOTA-F(ab ϵ) ₂ -trastuzumab in patients with breast cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 1157-1165.	0.5	68
21	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	1.1	63
22	Hypoxia in microscopic tumors. <i>Cancer Letters</i> , 2008, 264, 172-180.	3.2	60
23	Radiation Safety Considerations for the Use of ²²³ RaCl ₂ DE in Men with Castration-resistant Prostate Cancer. <i>Health Physics</i> , 2014, 106, 494-504.	0.3	59
24	Calculation of integrated biological response in brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 633-642.	0.4	53
25	A stereotactic method for the three-dimensional registration of multi-modality biologic images in animals: NMR, PET, histology, and autoradiography. <i>Medical Physics</i> , 2003, 30, 2303-2314.	1.6	52
26	Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody ¹²⁴ I-cG250. <i>Journal of Nuclear Medicine</i> , 2011, 52, 535-540.	2.8	47
27	¹²⁴ I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1878-1885.	2.8	47
28	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7014-7023.	3.2	47
29	Dosimetric Analysis of ¹⁷⁷ Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹ In-cG250 Imaging. <i>Journal of Nuclear Medicine</i> , 2012, 53, 82-89.	2.8	45
30	Hematologic Toxicity in Radioimmunotherapy: Dose-Response Relationships for I-131 Labeled Antibody Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 435-443.	0.7	44
31	Biodistribution and radiation dose estimates for ⁶⁸ Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 677-685.	3.3	44
32	Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA ϵ -MORAb-003. <i>Nuclear Medicine and Biology</i> , 2008, 35, 343-351.	0.3	42
33	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰ Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. <i>Journal of Nuclear Medicine</i> , 2015, 56, 805-811.	2.8	39
34	High ¹⁸ F-FDG Uptake in Microscopic Peritoneal Tumors Requires Physiologic Hypoxia. <i>Journal of Nuclear Medicine</i> , 2010, 51, 632-638.	2.8	38
35	⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832.	2.8	38
36	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1517-1523.	2.8	38

#	ARTICLE	IF	CITATIONS
37	Relevance of External Beam Dose-Response Relationships to Kidney Toxicity Associated with Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 378-387.	0.7	36
38	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	3.2	36
39	Image-Guided ^{18}F -Fluoromisonidazole Small-Animal PET Data in Rats. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1608-1615.	2.8	34
40	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1682-1691.	3.3	33
41	Iodination of annexin V for imaging apoptosis. <i>Journal of Nuclear Medicine</i> , 2002, 43, 671-7.	2.8	33
42	The Impact of Tumor Cell Proliferation in Radioimmunotherapy. <i>Cancer</i> , 1994, 73, 974-980.	2.0	31
43	^{18}F -Fluoromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 437-444.	2.8	31
44	Multiparametric Imaging of Tumor Hypoxia and Perfusion with ^{18}F -Fluoromisonidazole Dynamic PET in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1072-1080.	2.8	31
45	Bone Marrow Dosimetry Using ^{124}I -PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 615-621.	2.8	26
46	Pharmacokinetics and Biodistribution of a [^{89}Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 3083-3090.	2.3	26
47	Tumor Burden Assessment with Positron Emission Tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) Modeled in Metastatic Renal Cell Cancer. <i>Molecular Imaging and Biology</i> , 2000, 3, 57-65.	0.3	24
48	Detection of hypoxia in microscopic tumors using ^{131}I -labeled iodo-azomycin galactopyranoside (^{131}I -HAZGP) digital autoradiography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 339-348.	3.3	24
49	Copper-64 trastuzumab PET imaging: a reproducibility study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 191-198.	0.4	21
50	A Recommendation for Revised Dose Calibrator Measurement Procedures for ^{89}Zr and ^{124}I . <i>PLoS ONE</i> , 2014, 9, e106868.	1.1	20
51	Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3343-3351.	3.2	19
52	Comparison of ^{68}Ga -DOTA-JR11 PET/CT with dosimetric ^{177}Lu -satoreotide tetraxetan (^{177}Lu -DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3047-3057.	3.3	19
53	^{124}I -codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. <i>EJNMMI Research</i> , 2018, 8, 20.	1.1	17
54	Measurements of Partial Oxygen Pressure (pO ₂) using the OxyLite System in R3327-AT Tumors under Isoflurane Anesthesia. <i>Radiation Research</i> , 2006, 166, 512-518.	0.7	16

#	ARTICLE	IF	CITATIONS
55	In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nuclear Medicine and Biology, 2009, 36, 821-831.	0.3	15
56	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706.	3.3	13
57	Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. EJNMMI Research, 2013, 3, 42.	1.1	12
58	Image deconvolution in digital autoradiography: A preliminary study. Medical Physics, 2008, 35, 522-530.	1.6	11
59	Radiosynthesis of [131I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker " is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?. Nuclear Medicine and Biology, 2009, 36, 477-487.	0.3	10
60	Theranostics: The Role of Quantitative Nuclear Medicine Imaging. Seminars in Radiation Oncology, 2021, 31, 28-36.	1.0	10
61	Changes in FDG Tumor Uptake during and after Fractionated Radiation Therapy in a Rodent Tumor Xenograft. Molecular Imaging and Biology, 1999, 2, 289-296.	0.3	8
62	Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. EJNMMI Physics, 2021, 8, 6.	1.3	7
63	The effect on human neuroblastoma spheroids of fractionated radiation regimes calculated to be equivalent for damage to late responding normal tissues. European Journal of Cancer & Clinical Oncology, 1987, 23, 855-860.	0.9	6
64	Mathematical model of 5-[125I]iodo-2-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. International Journal of Radiation Oncology Biology Physics, 1998, 41, 1177-1183.	0.4	6
65	Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer. International Journal of Radiation Oncology Biology Physics, 1995, 32, 713-721.	0.4	5
66	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	3.3	4